Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2014 Mar 1.
Published in final edited form as: Womens Health Issues. 2013 Mar-Apr;23(2):10.1016/j.whi.2012.12.005. doi: 10.1016/j.whi.2012.12.005

Human Papillomavirus Vaccine Coverage Among Females Aged 11 to 17 in Texas Counties: An Application of Multilevel, Small Area Estimation

Jan M Eberth a,*, Md Monir Hossain b, Jasmin A Tiro c, Xingyou Zhang d, James B Holt d, Sally W Vernon e
PMCID: PMC3850179  NIHMSID: NIHMS447042  PMID: 23481692

Abstract

Background

Local data are often used to plan and evaluate public health interventions and policy. With increasingly fewer public resources to collect sufficient data to support direct estimation of local outcomes, methods for deriving small area estimates are vital. The purpose of this study is to describe the county-level geographic distribution of human papillomavirus (HPV) vaccine coverage among adolescent females in Texas using multilevel small area estimation.

Methods

Multilevel (individual, county, public health region) random-intercept logit models were fit to HPV vaccination data (≥1 dose Gardasil) from the 2008 Behavioral Risk Factor Surveillance System. Using the parameter estimates from the final model, we simulated 10,000 data sets for each regression coefficient from the normal distribution and applied them to the logit model to estimate HPV vaccine coverage in each county.

Results

County-level coverage estimates ranged from 7% to 29%, compared with the state average of 18% (95% confidence interval [CI], 13.59–21.88). Many Southwestern border and metropolitan counties exhibited high coverage estimates. Low coverage estimates were noted in the Panhandle, Southeastern border region, and Northeast. Significant correlations were observed between HPV vaccination and Hispanic ethnicity, county poverty, and public health region poverty.

Conclusion

Harnessing the flexibility of multilevel small area models to estimate HPV vaccine coverage at the county level, we have provided data that may inform the development of health education programs/policies, the provision of health services, and the planning of new research studies. Additionally, we have provided a framework for modeling other health outcomes at the county level using national survey data.

Introduction

The U.S. Food and Drug Administration approved the use of Gardasil (HPV4), a vaccine against four prevalent strains of human papillomavirus (HPV) for females aged 9 to 26 in June 2006 (U.S. Food and Drug Administration, 2006). Despite reports of high acceptability and willingness to vaccinate against HPV (Zimet, Liddon, Rosenthal, Lazcano-Ponce, & Allen, 2006), early research showed that uptake was suboptimal (Gottlieb et al., 2009; Jain, Stokley, & Yankey, 2008; Kahn et al., 2008; Rosenthal et al., 2008). Initiation of the HPV4 series (3 doses given over 6 months) grew over time, increasing to 48.7% of U.S. females aged 13 to 17 in 2010 (32% completed the vaccine series); however, initiation rates varied considerably by geographic region (range across 50 states, 28.8%–73.0%; Dorell, Stokley, Yankey, Liang, & Markowitz, 2011). In an analysis of 2008 Behavioral Risk Factor Surveillance System (BRFSS) data, Pruitt and Schootman (2010) found that HPV vaccine coverage differed significantly across states and counties, a finding explained in part by state- and county-level poverty. Although studies indicate the presence of geographic variation in HPV vaccine coverage across states and selected regions, and have found that group-level covariates such as poverty (Pruitt & Schootman, 2010) and education (Chao, Velicer, Slezak, & Jacobsen, 2010) are associated with HPV vaccination, local level estimates are not uniformly available in the literature.

Local data on HPV vaccine coverage are important for several reasons, including the planning of health promotion programs, identifying target populations for services (e.g., free vaccine clinics), and evaluating the impact of policies and programs designed to improve vaccine uptake. National health surveys provide much of the data used to conduct population-based public health research in the United States. Whereas these surveys provide estimates at the national, state, and sometimes county levels, their ability to provide local estimates is limited owing to costs, sample size constraints (i.e., ≥50 respondents per geographic unit recommended for direct estimation; Siegel, Frazier, Mariolis, Brackbill, & Smith, 1993), and privacy protections. Thus, researchers often rely on small area estimation (SAE), a set of indirect estimation techniques for producing small area estimates using data collected for larger areas and census tabulations for the small area of interest. This study used multilevel, SAE to describe the county-level geographic distribution of HPV vaccine coverage (≥1 dose HPV4) among females aged 11 to 17 years living in Texas. The methodological framework we discuss herein can be used by other researchers to analyze their own health outcome(s) of interest using a variety of national and state-based population surveys.

Analysis

Overview

In multilevel small area models (a type of synthetic estimation), model coefficients are linked with demographic- and geographic-specific population data (hereafter referred to as the auxiliary dataset) to predict the outcome for each small area or population subgroup. We applied multilevel SAE to predict county-level coverage of HPV vaccination. The 2008 BRFSS was used to develop a three-level (individual, county, public health region [PHR]), random-intercept logit model. Several factors informed our choice of covariates and model-building strategy. First, covariates included in the final model (both individual and group levels) were required to be available in both the individual and auxiliary datasets to permit estimation of small area means. Second, all individual- and group-level covariates considered for inclusion had known (Chao, Velicer, Slezak, & Jacobsen, 2009; Chao et al., 2010;Dempsey, Cohn, Dalton, & Ruffin, 2010; Dorell, Stokley, Yankey, Cohn, & Markowitz, 2010; Gottlieb et al., 2009; Neubrand, Breitkopf, Rupp, Breitkopf, & Rosenthal, 2009; Pruitt & Schootman, 2010; Rondy, van Lier, van de Kassteele, Rust, & de Melker, 2010) or hypothesized associations with HPV vaccination in adolescents. Finally, because Texas counties are nested within PHRs and vaccine coverage data in Texas is often presented for PHRs, we included PHR-level random effects in the model to ensure the correct selection of group-level covariates and parameter estimates. A summary of these methods is shown in Figure 1.

Figure 1.

Figure 1

Summary of data collection, management, and analysis strategy. PCA, principal component analysis; PHR, public health region. aPreliminary model includes age, race/ethnicity, parental education, county and PHR poverty. bTechnical documentation (i.e., equations/Equ.) can be found in Appendix A. cFinal model includes all the variables from the preliminary model except for parental education. Although parental education is an important predictor of HPV vaccination, it could not be included in the final model because the corresponding variable was not present in the Auxiliary Dataset. A post-adjustment method, described by Congdon (25), was used as an alternative to inclusion of parental education in the final model.

SAS Version 9.1 (SAS Institute, Cary, NC) was used for data management and MLwiN Version 2.20 was used to implement multilevel models. Our study was granted exempt status by our Institutional Review Board.

Data Collection and Management

We used the 2008 Texas BRFSS (U.S. Centers for Disease Control and Prevention, 2008b) to obtain the dependent variable and individual-level covariates of interest. County- and PHR-level data were acquired from multiple sources including the Association of Religious Data Archives, U.S. Department of Agriculture Office of Management and Budget, Texas Cancer Registry, Texas Department of Health and Human Services, and U.S. Census Small Area Health Insurance Estimates Program. County-specific population estimates, stratified by gender, age, and race/ethnicity (the auxiliary dataset), were obtained from the Vintage 2008 Bridged-Race Postcensal Population Estimates file available from the Health Center for Health Statistics (Centers for Disease Control and Prevention, 2009).

The BRFSS is a population-based, random digit-dial survey conducted annually by the states, through a cooperative agreement with the U.S. Centers for Disease Control and Prevention. In addition to the core questions asked by all states in 2008, Texas adopted the optional HPV modules. In Texas, the proportion of contacted persons who completed the interview was 75% (Centers for Disease Control and Prevention, 2008a). Information on the survey design and sampling strategy are available elsewhere (Centers for Disease Control and Prevention, 2008a, 2008b).

When children resided in the home of an adult respondent (referred to as the parent/caregiver), he or she answered questions about one randomly selected child. Our sample consisted of 574 parents/caregivers, all of whom 1) had a county of residence listed in the public use dataset, 2) had a randomly selected 11- to 17-year-old daughter for whom survey data were collected, and 3) reported their level of educational attainment. The daughter’s age and race/ethnicity, as well as the parent/caregiver’s educational attainment, are known predictors of HPV vaccine uptake (Chao et al., 2009, 2010; Conroy et al., 2009; Dempsey et al., 2010; Dorell et al., 2010; Gottlieb et al., 2009; Neubrand et al., 2009; Pruitt & Schootman, 2010; Wong et al., 2011); thus, any person with missing data on these items was excluded. Additionally, participants who did not know their daughter’s HPV vaccination status were excluded. These criteria reduced the sample size from 623 to 574.

In selecting group-level covariates for examination, we made an a priori decision to include county-level poverty because of its known positive association with HPV vaccine initiation (Pruitt & Schootman, 2010). Because the majority of covariates of interest had not been previously studied, we implemented an exploratory approach to select additional covariates for examination. We were specifically interested in testing the effects of access, religious adherence, sexually transmitted disease and cervical cancer prevalence, and uptake of other childhood and adolescent vaccines. When there were multiple measures representing a specific concept (e.g., access to care could be measured by density of physicians or Vaccines For Children providers in the county, urban/rural classifications, or designation as a Health Professional Shortage Area), we conducted principal components analysis to extract one representative covariate for each concept. The covariate with the strongest correlation to the first principal component was then examined in our models. Principal components analysis was not done for PHR-level covariates because of limited variability (n = 11). This approach resulted in examination of the group-level covariates listed in Table 1.

Table 1.

Model-Building Strategy for Determining the Final Model of HPV Vaccine Initiation among Texas Females Aged 11 to 17

Step Model Type* Covariates Examined Covariates Retained
1 Empty model N/A N/A
2 Covariates at level 1 Child’s age Child’s age
Child’s race/ethnicity Child’s race/ethnicity
Parental education Parental education
3 Covariates at levels 1 and 2 Child’s age Child’s age
Child’s race/ethnicity Child’s race/ethnicity
Parental education Parental education
County poverty (%) County poverty (%)
County chlamydia rate
County cervical cancer incidence rate
County polio vaccination (%) among 7th graders
County measles vaccination (2nd dose, %) among kindergarteners
County rurality index (metropolitan, micropolitan, noncore)
County uninsurance (%)
County evangelical religious adherence rate
4 Covariates at all levels: Preliminary model Child’s age Child’s age
Child’s race/ethnicity Child’s race/ethnicity
Parental education Parental education
County poverty (%) County poverty (%)
PHR poverty (%) PHR poverty (%)
PHR chlamydia rate
PHR cervical cancer incidence rate
PHR polio vaccination (%) among 7th graders
PHR measles vaccination (2nd dose, %) among kindergarteners
PHR uninsurance (%)
5 Covariates at all levels: Final model N/A Child’s age
Child’s race/ethnicity
County poverty (%)
PHR poverty (%)

Abbreviations: HPV4, Gardasil; N/A, not applicable; PHR, public health region.

*

All models contain both county- and PHR-level random intercepts.

Although sampling weights are provided by the BRFSS, they are not efficient for use in small area models because the weights are constructed at the state level. The problem is compounded for multilevel models, which traditionally have not made use of weights associated with complex survey data (Carle, 2009). As suggested by Carle (2009) and Rabe-Hesketh and Skrondal (2006), we rescaled the level 1 sampling weights (i.e., CHILDWT) to produce better point estimates and reduce the risk of biased estimates when the cluster size is small. We also included weights at levels 2 and 3 as proposed by Goldstein (2010). Technical documentation for the scaling and creation of these weights is provided in Appendix A.

Statistical Analysis

The outcome was initiation of HPV vaccination (≥1 dose HPV4, yes or no) among females aged 11 to 17. A series of increasingly complex models were fit to the data, starting with the empty model and adding covariates sequentially by level (Table 1). Level 1 covariates were added to the empty model in step 2 and were retained for inclusion regardless of statistical significance in steps 3 through 5. At steps 3 and 4, group-level covariates were added to the model simultaneously. Covariates were removed from the model sequentially, starting with the least significant, until only covariates with p ≤ .1 remained. Using a more conservative 0.25 p-value, as suggested by Hosmer and Lemeshow (2000), resulted in the same selection of covariates. Because auxiliary data were only stratified by age and race/ethnicity, parental education was removed from the final model (step 5). A post-estimation adjustment for education at the county-level was incorporated as suggested by Congdon (2009; equation in Appendix A). First-order marginal quasi-likelihood, followed by second-order penalized quasi-likelihood (uses marginal quasi-likelihood estimates as starting values; provides robust estimates when sample sizes are small), was used in all models. Interaction terms were not tested owing to the small sample size.

We applied the parameter estimates from the final model to simulate 10,000 probabilities of HPV vaccine uptake for each race- and age-specific subgroup each county. The probabilities were adjusted for the educational mix of each county. We then calculated the mean value, standard deviation, and 95% confidence interval (CI) of these simulated subgroup probabilities. The variance associated with the PHR-level random intercept was very small and thus ignored in the simulation. The county random intercept was only estimated for sampled counties in the 2008 Texas BRFSS. Finally, we multiplied the race- and age-specific adjusted probabilities above by the corresponding county subpopulation to generate summary estimates of HPV vaccine coverage for each county.

To test the accuracy of our multilevel model, we aggregated our county-level estimates up the state level and compared the resulting model-based estimate with the direct estimate of HPV vaccine coverage at the state level. We did the same validation checks with our age- and race-specific county estimates. These analyses allow us to examine whether our small area estimates (aggregated up to the state level) produce the expected results at the state level, where direct estimation of HPV vaccine coverage is possible.

Results

Sample Characteristics

Our sample consisted of 574 parents/caregivers residing in 99 Texas counties (39% of counties). The adolescent females were primarily White (54%) or Hispanic (33%), with educated parents/caregivers (34% had a bachelor’s degree or higher and 27% had some college education), and a mean age of 14 years. The large majority of respondents (88%) indicated they were parents (biologic, step, or adoptive) of the adolescent female. Many of the participants came from large metropolitan counties including Bexar (n = 55), El Paso (n = 44), Harris (n = 40), Lubbock (n = 31), Tarrant (n = 31), Travis (n = 36), and Val Verde (n = 30), which is not surprising given their greater probability of being selected as a survey participant.

Model Results

In all models, there was small variability at the county- and PHR-level (Table 2). At the county level, we evaluated the area level variance using the median odds ratio (MOR) (not able to be estimated at the PHR-level). Because the MOR was not far from 1.00 in the final model, we concluded that there were minimal differences between counties in the individual probability of obtaining HPV vaccination.

Table 2.

Random-Intercept Logit Models of HPV Vaccine Initiation among Texas Females Aged 11 to 17

Parameters Model 1, OR (95% CI) Model 2, OR (95% CI) Model 3, OR (95% CI) Model 4, OR (95% CI) Model 5, OR (95% CI)
Fixed effects
 Intercept 0.26 (0.21–0.32) 0.10 (0.02–0.50) 0.05 (0.01–0.30) 0.09 (0.01–0.72) 0.16 (0.03–0.82)
 Child’s age N/A 1.03 (0.93–1.14) 1.03 (0.93–0.14) 1.03 (0.92–1.14) 1.03 (0.94–1.12)
 White N/A Ref Ref Ref Ref
 Black N/A 1.04 (0.33–3.23) 1.06 (0.35–3.22) 1.02 (0.34–3.06) 0.93 (0.31–2.76)
 Hispanic N/A 2.00 (1.48–2.70) 1.70 (1.17–2.47) 1.77 (1.28–2.46) 1.34 (0.95–1.91)
 Other races N/A 1.28 (0.51–3.20) 1.25 (0.46–3.40) 1.24 (0.42–3.63) 1.29 (0.45–3.71)
 <HS education N/A Ref Ref Ref N/A
 HS graduate N/A 0.78 (0.37–1.66) 0.82 (0.39–1.73) 0.85 (0.40–1.77) N/A
 Some college N/A 1.80 (0.88–3.66) 1.94 (0.94–4.02) 1.97 (0.95–4.10) N/A
 ≥Bachelor’s N/A 1.72 (0.94–3.16) 1.84 (0.98–3.48) 1.84 (0.97–3.47) N/A
 County poverty* N/A N/A 1.05 (0.99–1.11) 1.09 (1.02–1.18) 1.09 (1.02–1.17)
 PHR poverty N/A N/A N/A 0.92 (0.86–0.99) 0.92 (0.86–0.98)

Abbreviations: CI, confidence interval; HPV4, Gardasil; HS, high school; OR, odds ratio; PHR, public health region; SE, standard error.

*

County- and PHR-level poverty were measured continuously.

Hispanic ethnicity was the only significant level 1 covariate. Compared with Whites, Hispanic females aged 11 to 17 were significantly more likely to be vaccinated against HPV (odds ratio [OR], 1.77; 95% CI, 1.28–2.46). The removal of parental education from the final model impacted the strength and significance of the covariate (OR, 1.34; 95% CI, 0.95–1.91), suggesting a possible suppression effect. We suspect the likely reason for this effect is educational distribution across racial/ethnic groups. In our sample, Whites, Blacks, and other races had positively skewed distributions (i.e., toward more education), whereas Hispanics had a negative skew. In contrast with several studies finding a positive effect of age on HPV vaccine uptake (Chao et al., 2010; Conroy et al., 2009; Dempsey et al., 2010; Gottlieb et al., 2009; Pruitt & Schootman, 2010), we found a null effect that likely reflects how we defined the variable (i.e., continuous vs. categorical).

We found a significant, positive association between county-level poverty and HPV vaccination. The odds of being vaccinated increased by about 9% for every 1% increase in county-level poverty. A more meaningful interpretation, based on the distribution of poverty in Texas (range across counties, 6.2%–36.8%), would be the change in odds for every 5% or 10% change in county-level poverty. For these values, we would expect to see the odds of vaccination increase by 54% and 139%, respectively. Our model also showed a significant, negative association between PHR-level poverty and HPV vaccination. Thus, for a 5% or 10% change in PHR-level poverty (vs. a 1% change, as shown in Table 2), the odds of vaccination decreased by 35% and 58%, respectively.

Small Area Estimates

In 2008, 17.7% (95% CI, 13.59–21.88) of Texas females aged 11 to 17 were vaccinated against HPV (based on direct, weighted estimation of HPV vaccine initiation data from the 2008 Texas BRFSS). That same year, the national average for females aged 11 to 17 was 30.4%. County-level model-based small area estimates ranged from 6.8% to 29.0% (Figure 2; Appendix B). No estimate is provided for Loving county because there were no representative females. The state-level indirect estimate was 15.5% (95% CI, 14.1–16.9), which lies within the confidence interval of its direct estimate of HPV vaccine coverage (95% CI, 13.59–21.88). Our race/ethnicity- and age-specific indirect estimates, scaled up to the state level, were also within the confidence intervals of their respective direct estimates, with the exception of the indirect estimate for HPV vaccine coverage among 13-year-old girls in Texas (Table 3).

Figure 2.

Figure 2

County-level estimates of HPV vaccine coverage among females aged 11 to 17 in Texas.

Table 3.

Comparison of Indirect and Direct Estimation of Human Papilloma Virus (HPV) Vaccine Coverage at the State Level

HPV Vaccine Coverage
in Texas
Indirect Estimate
(95% CI)
Direct Estimate
(95% CI)
Texas 15.51 (14.14–16.93) 17.74 (13.59–21.88)
Texas, racial/ethnic
  categories
 White 13.55 (11.93–15.32) 13.69 (9.18–18.82)
 Black 14.45 (11.46–17.72) 21.70 (5.97–37.42)
 Hispanic 17.61 (15.00–20.31) 22. 42 (14.03–30.80)
 Other races 16.27 (13.19–19.60) 23.75 (0–54.58)
Texas, age categories (yrs)
 11 14.70 (11.41–28.50) 11.48 (3.55–19.41)
 12 14.94 (11.63–18.73) 12.20 (5.95–18.46)
 13 15.25 (11.88–19.18) 27.81 (16.71–38.92)
 14 15.55 (12.13–19.37) 14.53 (4.84–24.22)
 15 15.78 (12.24–19.64) 27.69 (12.80–42.59)
 16 16.04 (12.55–19.85) 16.68 (7.89–25.46)
 17 16.32 (12.82–20.28) 15.95 (6.37–25.53)

Discussion

Researchers have used model-based SAE to examine a variety of health behaviors and outcomes including asthma, obesity, smoking, mammography utilization, and health insurance coverage (Congdon, 2010; Goodman, 2010; Li, Land, Zi, Keithly, & Kelsey, 2009; Mendez-Luck, Yu, Meng, Jhawar, & Wallace, 2007; Schneider, Lapane, Clark, & Rakowski, 2009; Yu, Meng, Mendez-Luck, Jhawar, & Wallace, 2007). Using BRFSS data, Jia, Muennig, and Borawski (2004) found that regression models provided better precision than traditional synthetic and spatial smoothing methods in SAE. Multilevel modeling is a particularly useful SAE approach because it simultaneously examines individual and place-based factors, and borrows strength from the global model to make small area inferences. The increasing availability of software products that can be used to perform multilevel SAE using weighted survey data (e.g., MLwiN, STATA’s GLAMM, and Mplus), makes it possible for researchers without formal training in statistics to conduct small area research.

Examining health behaviors and outcomes at the local level facilitates policy making, program development and evaluation, and hypothesis generation. At the policy end, legislators need information about their jurisdictions to make informed choices about bills related to health education programs and mandates. For example, Mendez-Luck and co-workers (2007) provided asthma prevalence data at the Assembly district level in California to assist in advocacy and policy-making activities. With data on disease rates over space and time, healthcare administrators and researchers can also develop and evaluate health promotion and outreach programs, targeted and tailored to the communities with the greatest needs. Finally, SAE provides a foundation for hypothesis generation. Knowing which areas are most affected by a particular disease, or conversely, which have the best health behaviors, can lead to formulating and testing hypotheses about the causal mechanisms involved.

SAE is ideal for studying HPV vaccination for several reasons, including the following: 1) The Texas ImmTrac Vaccine Registry is a voluntary “opt-in” program, which limits the generalizability of the data, and 2) the data are not actively collected by schools or public health departments since it is not required for entry into Texas public schools. Our findings indicate wide variability in HPV vaccine coverage across counties (7%–29%). Many of the Southwest border counties exhibited high coverage rates, as did many large, metropolitan counties (e.g., Dallas, Brazos). Low coverage rates were common in the Panhandle (i.e., northern-most counties), Southeast border region, and the Northeast. Our multilevel model also showed some counterintuitive findings. Although county-level poverty was associated with increased odds of vaccination, PHR-level poverty was associated with decreased odds. Our findings paralleled those reported by Pruitt and Schootman (2010), in which HPV vaccination was positively associated with county-level poverty and negatively associated with state-level poverty. This suggests that county-level poverty may be more indicative of better financed public health programs and/or is strongly related to the racial/ethnic makeup of the county. However, not all counties were represented in our sample, which may have resulted in a biased measure of association for county-level poverty. The ability to interpret our findings on PHR-level poverty is limited by two issues: 1) PHR-level poverty represents a greater scale of geographic aggregation (i.e., sets of geographically contiguous counties, typically anchored by at least one metropolitan area), resulting in limited data variability and generalizability, and 2) the sample of respondents within each PHR varied widely, with some PHRs having respondents drawn from multiple counties and others having respondents from only one or two counties.

SAE has some inherent limitations. First, not all covariates of interest can be included. At level 1, only those covariates that are present in both the individual-level and auxiliary dataset can be included. It is possible, however, to make post-model adjustments (as we did for education) at the expense of model simplicity. Second, having no or few respondents at higher levels can limit estimation of random effects. In our study, we handled this by assigning the mean of simulated random effects to all non-sampled counties. Alternatively, one can ignore the random effects altogether (as we did for PHRs). Finally, there is often no gold standard for comparison of small area estimates. Without a reference, one cannot easily assess the accuracy of small area estimates. Several methods have been proposed to deal with this issue, including cross-validation using part of the sample, a different dataset, or data from another year (as long as the outcome is stable over time), as well as aggregation of one’s estimates to a higher geographic level, where direct estimation and thus comparison and calibration (Yu et al., 2007) are possible.

Two lines of future research are proposed: Examination of how alternate modeling strategies might affect our estimates, and estimation of HPV vaccine coverage in other population groups. Alternative modeling strategies include 1) use of different sampling weights, 2) specifying other hierarchical structures, 3) removing random effects, 4) adding a spatial component to incorporate neighborhood information, and 5) evaluating the potential of other software programs (e.g., STATA’s GLAMM procedure) to perform similar analyses with greater ease. Estimation of vaccine coverage among other population groups, such as males aged 9 to 26 and females aged 18 to 26, is also warranted.

Acknowledgments

This work was supported by National Cancer Institute preand post-doctoral fellowships (R25-CA057712, R25-CA57730) and a National Institutes of Health Cancer Center Support Grant (CA016672). The authors wish to acknowledge the excellent editorial contributions of Dr. Sandi Pruitt (UT Southwestern), Dr. Graham Moon (University of Southampton), and the Doctoral Behavioral Science Seminar at the University of Texas, School of Public Health at Houston. We also thank Dr. Christina Dorell, from the Centers for Disease Control & Prevention, whose suggestions were integral to the planning of this study. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the National Cancer Institute, the National Institutes of Health, or the Centers for Disease Control and Prevention. Gardasil is a registered trademark of Merck & Co., Inc.

Author Descriptions

Jan M. Eberth, PhD, is an Assistant Professor of Epidemiology at the University of South Carolina, Arnold School of Public Health. Her research focuses on disparities in access, utilization, and quality of cancer prevention and treatment services.

Md Monir Hossain, PhD, is an Assistant Professor in the Department of Pediatrics at Cincinnati Children’s Hospital Medical Center. Dr. Hossain works to develop innovative statistical methods for cluster detection and small area health analyses.

Jasmin A. Tiro, PhD, is an Assistant Professor in the Department of Clinical Sciences at the University of Texas Southwestern Medical Center. Her research centers on evaluating HPV vaccination behavior and cancer prevention delivery in clinical settings.

Xingyou Zhang, PhD, is a geographer and statistician in the Division of Adult and Community Health at the Centers for Disease Control and Prevention. Dr. Zhang’s research focuses on the integration of geographic information and technology in epidemiologic studies.

James B. Holt, PhD, is a geographer in the Division of Adult and Community Health at the Centers for Disease Control and Prevention, and Team Leader of the Analytic Methods Branch. He utilizes geospatial data and methods for chronic disease prevention research.

Sally W. Vernon, PhD, is Professor of Epidemiology and Behavioral Sciences at The University of Texas Health Science Center at Houston School of Public Health. She is recognized for her work in the area of behavioral research to promote cancer screening.

Appendix A. Technical Documentation of Methods

[Equation 1: General]

logit(pijk)=γ0j+γ0k+β1Level 1 Variablesijk+β2,jkLevel 2 Variablesjk+β3,kLevel 3 Variabkesk

[Equation 1 – Applied Preliminary Model]

logit(pijk)=β0j+β0k+β1Ageijk+β2<HSijk+β3HSgraduateijk+β4Some collegeijk+β5Bachelors plusijk+β6Whitwijkβ7Blackijk+β8Hispanicijk+β9Other racesijk+β10,jkCountry Povertyjk+β11,kPHR Povertyk

where:

  • β0j = β0 μj (country – level random – intercept).

  • β0k = β0 + μk (PHR – level random – intercept).

  • β1 = Regression coefficient for age.

  • β1 = Regression coefficient for < High school education (reference)

  • β3 = Regression coefficient for HS graduate.

  • β4 = Regression coefficient for some college.

  • β5 = Regression coefficient for Bachelors plus.

  • β6 = Regression coefficient for White (reference).

  • β7 = Regression coefficient for Black.

  • β8 = Regression coefficient for Hispanic.

  • β9 = Regression coefficient for other races.

  • β10 = Regression coefficient for country poverty.

  • β11 = Regression coefficient for PHR poverty.

  • i (subjects) = 1,…,mjk

  • j (county) = 1,…,nk

  • k (PHR) = 1,…,11.

  • μ = area level variance.

[Equation 2: Applied final model]

logit(pijk)=β0j+β0k+β1Ageijk+β06Whiteijk+β7Blackijk+β8Hispanicijk+β9Other racesijk+β10,jkCountry Povertyijk+β11,kPHR Povertyk

where:

  • β0j = β0j + μj (county – level random – intercept)

  • β0k = β0 + μk (PHR – level random – intercept)

  • * μk will be set to 0 in the simulations and calculation of small area means.

  • β0j = β0 + μj (county – level random – intercept)

  • β0k = β0 + μk (PHR – level random – intercept)

  • β1 = Regression coefficient for age.

  • β6 = Regression coefficient for White (reference)

  • β7 = Regression coefficient for Black.

  • β8 = Regression coefficient for Hispanic.

  • β9 = Regression coefficient for other races.

  • β10 = Regression coefficient for county poverty.

  • β11 = Regression coefficient for PHR poverty.

  • i (subjects) 1,…,mjk

  • j (county) =1,…,nk

  • k (PHR) = 1,…,11.

  • μ = area level variance.

[Equation 3: Weighted regression coefficients for education]

Lj=πej×[exp(βxEducationijk)/1]+exp(βxEducationijk)

where:

  • x = 1 – 4.

  • i (subjects) 1,…,mjk

  • j (county) =1,…,nk

  • k (PHR) = 1,…,11.

π∣e = the proportion of persons in county j with educational attainment e

[Equation 4: Simulated mean random effect (level 2 only)]

xijnormal(μi,σi2)(parameters from MLwiN)x¯i=110,000xij(for sampled countries)x¯=199x¯i(for nonsampled countries)

where:

  • i = 1, 2, …, 99 (number of sampled counties, and thus estimated random effects).

  • j = 1, 2, …, 10,000 (number of simulations).

[Equation 5: Simulated means and 95% confidence intervals, adjusted for county education]

Step 1: Simulations

  • β0normal(1.839,0.835)β1normal(0.025,0.047)β7normal(0.075,0.556)β8normal(0.299,0.177)β9normal(0.254,0.539)β10normal(0.087,0.034)β11normal(0.085,0.032)
  • xijnormal(μi,σi2)rijnormal(x¯,σi2)

* Values taken from the model (i.e., regression coefficients and standard errors).

Step 2: Calculate adjusted means

Race- and age-specific county means:

p¯RAj=1n(expβ0+(xijorrij)+β1age+etc1+expβ0+(xijorrij)+β1age+etcLj)

Age-specific county means:

p¯Aj=(NRAjpRAj)NAj

Race-specific county means:

p¯Rj=(NRAjpRAj)NRj

County means:

p¯j=(NRAjpRAj)Nj

Step 3: Calculate standard deviation

SRAj=1n1(pRAjp¯RAj)2SAj=1n1(pAjp¯Aj)2SRj=1n1(pRjp¯Rj)2Sj=1n1(pjp¯j)2

Step 4: Calculate 95% confidence interval

95%CI=p¯RAj±t(1a2;n1)(Sn)

where:

  • β0 = Intercept.

  • β1 = Regression coefficient for age.

  • β7 = Regression coefficient for race (Black vs. White)

  • β8 = Regression coefficient for race (Hispanic vs. White)

  • β9 = Regression coefficient for race (other races vs. White)

  • β10 = Regression coefficient for county poverty.

  • β11 = Regression coefficient for PHR poverty.

  • L = weighted regression coefficient for education.

  • RA = race and age specific.

  • A = age specific.

  • R = race specific.

  • j = county specific.

  • n = 10,000 (number of simulations)

  • t = 1.96 (from Student’s t distribution)

  • N = population count

pRAj=expβ0+β1age+etc1+expβ0+β1age+etcLj
  • p = probability of vaccination.

  • s = standard deviation of simulated mean.

  • μ = area level variance.

  • X¯ = simulated mean random effect for nonsampled counties (see equation 4).

[Equation 6: Calculation of median odds ratio]

Step 1: Calculate median odds ratio

Median Odds Ratio(MOR)=exp0.95μj

where:

  • μ = area level variance.

  • j = county-specific.

[Equation 7: Level 2 weight calculation]

wk=WkK/Wk

where Wk=iwiknk,

  • nk = number of respondents in a county (or PHR)

  • wik = raw CHILDWT values.

  • K = 254 (11 for PHR)

* We extended this formula to the level 3 (PHR) weights.

Appendix B.

Appendix B.

County-Level Estimates of Human Papilloma Virus Vaccine Coverage among Females Aged 11 to 17: Texas, 2008

County name Mean (%) Lower 95% CI (%) Upper 95% CI (%)
Anderson 18.00 11.84 25.08
Andrews 13.87 8.48 20.18
Angelina 16.29 10.59 22.76
Aransas 9.92 5.11 16.10
Archer 9.01 4.32 15.61
Armstrong 10.17 4.87 17.57
Atascosa 16.44 9.83 23.81
Austin 11.94 7.42 17.24
Bailey 15.71 9.51 22.83
Bandera 12.46 7.06 19.29
Bastrop 13.56 8.78 19.15
Baylor 15.59 9.23 23.21
Bee 16.64 9.08 25.17
Bell 14.18 9.44 19.51
Bexar 16.54 10.33 23.67
Blanco 11.87 6.86 17.95
Borden 10.24 4.82 18.13
Bosque 13.91 8.16 20.92
Bowie 16.56 10.25 23.79
Brazoria 11.78 7.62 16.82
Brazos 24.96 17.97 32.09
Brewster 11.27 5.97 17.78
Briscoe 13.93 8.49 20.28
Brooks 19.63 9.43 30.88
Brown 14.98 9.08 22.14
Burleson 14.60 9.37 20.79
Burnet 13.28 7.90 19.71
Caldwell 15.20 9.91 21.18
Calhoun 14.42 9.05 20.52
Callahan 12.94 7.06 20.23
Cameron 20.61 10.34 31.72
Camp 15.10 9.94 20.86
Carson 9.37 4.68 15.88
Cass 15.32 9.06 22.62
Castro 18.06 11.38 25.49
Chambers 10.84 6.47 16.28
Cherokee 19.08 12.79 26.22
Childress 21.34 14.55 28.52
Clay 10.32 5.08 17.31
Cochran 19.62 12.80 26.98
Coke 14.59 8.76 21.60
Coleman 18.34 11.00 26.52
Collin 10.80 6.76 15.98
Collingsworth 18.20 11.51 25.91
Colorado 17.30 11.61 23.50
Comal 9.60 5.50 14.98
Comanche 15.96 9.73 23.04
Concho 22.95 15.24 31.12
Cooke 13.54 8.16 20.00
Coryell 14.67 9.45 20.87
Cottle 18.42 12.09 25.34
Crane 11.79 6.95 17.51
Crockett 14.18 8.21 21.33
Crosby 20.90 13.52 28.78
Culberson 15.21 8.01 23.50
Dallam 12.55 7.59 18.34
Dallas 18.95 13.59 24.85
Dawson 20.19 13.23 27.51
Deaf-Smith 17.68 10.51 25.49
Delta 16.43 9.19 25.13
Denton 10.63 6.66 15.78
DeWitt 16.63 10.96 23.01
Dickens 22.77 14.93 30.99
Dimmit 28.99 19.13 38.48
Donley 15.41 8.55 23.77
Duval 15.06 6.66 24.83
Eastland 16.40 9.50 24.38
Ector 15.70 9.80 22.50
Edwards 19.67 12.57 27.41
El-Paso 12.27 7.82 17.71
Ellis 17.23 8.64 26.86
Erath 19.73 12.79 27.57
Falls 21.68 15.64 27.95
Fannin 16.35 9.73 23.93
Fayette 12.07 7.31 17.90
Fisher 13.67 8.53 19.93
Floyd 19.32 12.49 26.82
Foard 15.23 8.83 22.85
Fort-Bend 11.18 7.61 15.34
Franklin 13.82 8.21 20.85
Freestone 13.90 8.70 20.08
Frio 25.20 15.37 34.89
Gaines 16.06 10.15 22.65
Galveston 13.38 8.76 18.80
Garza 18.96 12.46 26.19
Gillespie 10.03 5.50 15.85
Glasscock 10.56 5.80 16.77
Goliad 13.41 7.93 19.85
Gonzales 16.50 10.72 22.87
Gray 13.26 7.81 19.85
Grayson 13.92 8.17 20.96
Gregg 13.19 8.33 18.79
Grimes 14.32 9.31 20.10
Guadalupe 10.99 6.57 16.11
Hale 17.50 11.06 24.67
Hall 20.89 14.36 27.97
Hamilton 13.27 7.07 21.31
Hansford 11.89 6.86 17.88
Hardeman 15.51 9.61 22.57
Hardin 10.79 5.40 17.81
Harris 16.45 11.41 21.95
Harrison 13.28 8.16 19.44
Hartley 10.10 5.23 16.68
Haskell 19.07 12.33 26.58
Hays 15.44 9.99 21.75
Hemphill 9.48 5.03 15.44
Henderson 13.71 7.89 20.69
Hidalgo 21.30 10.54 32.87
Hill 15.60 9.79 22.24
Hockley 16.24 10.30 22.99
Hood 12.38 6.81 19.31
Hopkins 13.86 8.19 20.66
Houston 20.39 13.68 27.74
Howard 19.88 13.34 26.88
Hudspeth 19.97 11.20 29.42
Hunt 15.24 9.40 22.04
Hutchinson 11.38 6.64 17.24
Irion 10.90 6.49 16.37
Jack 13.02 7.24 20.32
Jackson 12.29 7.65 18.01
Jasper 15.73 9.33 23.17
Jeff-Davis 8.21 4.08 14.07
Jefferson 14.06 9.31 19.54
Jim-Hogg 12.65 5.31 21.98
Jim-Wells 11.71 5.47 19.74
Johnson 11.76 6.92 17.74
Jones 19.85 12.89 27.32
Karnes 23.42 15.94 30.90
Kaufman 11.89 7.37 17.34
Kendall 9.20 4.97 14.76
Kenedy 8.99 3.42 17.27
Kent 10.67 4.77 18.98
Kerr 12.72 7.57 19.01
Kimble 16.37 10.25 23.24
King 12.20 5.63 21.43
Kinney 19.43 11.96 27.55
Kleberg 13.93 7.05 22.39
Knox 18.13 12.12 24.97
La-Salle 15.09 8.93 22.33
Lamar 19.19 12.32 26.53
Lamb 14.81 9.16 21.63
Lampasas 25.47 15.58 35.35
Lavaca 11.45 6.62 17.51
Lee 13.02 8.20 18.52
Leon 14.05 8.46 20.66
Liberty 15.62 9.87 22.31
Limestone 16.80 11.24 23.04
Lipscomb 12.17 7.20 18.16
Live-Oak 9.10 4.47 14.90
Llano 13.25 7.42 20.44
Loving N/A N/A N/A
Lubbock 14.83 9.46 20.93
Lynn 17.26 11.17 24.25
Madison 20.78 13.92 28.14
Marion 19.37 13.61 25.78
Martin 6.82 2.98 12.52
Mason 19.19 13.08 25.82
Matagorda 18.00 11.25 25.70
Maverick 15.44 9.78 22.16
McCulloch 14.12 8.37 21.01
McLennan 18.08 12.51 23.98
McMullen 23.60 13.46 33.92
Medina 15.30 9.43 22.06
Menard 19.88 12.53 27.84
Midland 11.89 7.32 17.39
Milam 15.63 10.35 21.73
Mills 17.18 10.46 24.95
Mitchell 22.24 15.01 29.76
Montague 12.42 6.52 19.80
Montgomery 11.39 6.79 17.22
Moore 13.08 7.60 19.56
Morris 15.16 9.53 21.72
Motley 16.49 10.15 24.01
Nacogdoches 18.56 12.61 24.98
Navarro 18.77 13.00 25.00
Newton 16.49 10.10 23.58
Nolan 17.94 11.79 24.85
Nueces 9.53 4.70 15.90
Ochiltree 12.04 7.02 17.94
Oldham 12.67 6.85 19.87
Orange 11.04 5.85 17.86
Palo-Pinto 14.99 9.11 21.84
Panola 12.45 7.31 18.89
Parker 12.47 6.90 19.68
Parmer 13.72 7.92 20.82
Pecos 19.71 12.30 27.68
Polk 12.35 7.38 18.54
Potter 19.98 13.84 26.61
Presidio 13.69 6.10 22.97
Rains 13.64 7.52 21.31
Randall 9.32 5.06 15.22
Reagan 10.89 6.07 17.03
Real 16.56 10.00 24.20
Red-River 15.75 9.67 22.78
Reeves 25.30 15.78 34.76
Refugio 7.86 3.89 12.97
Roberts 8.29 3.57 15.45
Robertson 18.58 12.82 24.85
Rockwall 10.20 5.96 15.84
Runnels 16.31 10.21 22.96
Rusk 14.06 8.84 20.64
Sabine 12.07 6.19 19.57
San-Augustine 18.34 11.32 25.94
San-Jacinto 14.90 8.78 22.10
San-Pactricio 8.99 4.52 14.76
San- Saba 20.19 13.19 27.61
Schleicher 14.75 8.90 21.40
Scurry 16.53 10.65 23.10
Shackelford 11.06 5.52 18.26
Shelby 18.44 12.27 25.30
Sherman 13.58 8.25 19.82
Smith 12.75 8.15 18.43
Somervell 11.94 6.93 18.33
Starr 22.17 10.95 34.06
Stephens 15.68 9.41 22.84
Sterling 12.42 6.87 19.17
Stonewall 14.49 8.35 21.88
Sutton 12.37 7.30 18.35
Swisher 17.56 11.35 24.52
Tarrant 14.59 9.85 20.01
Taylor 14.91 9.45 21.19
Terrell 19.82 12.74 27.37
Terry 21.57 14.44 29.00
Throckmorton 12.85 6.41 21.35
Titus 14.20 9.03 20.20
Tom-Green 14.99 9.68 21.21
Travis 15.93 10.77 21.74
Trinity 16.06 9.79 23.62
Tyler 15.21 8.38 23.15
Upshur 12.82 7.07 19.83
Upton 14.65 8.88 21.20
Uvalde 21.84 13.39 30.41
Val-Verde 18.91 10.80 27.96
Van-Zandt 13.56 7.35 21.11
Victoria 14.47 9.08 20.65
Walker 22.09 15.67 28.81
Waller 15.88 10.59 21.54
Ward 15.96 10.24 22.37
Washington 13.55 8.61 19.38
Webb 16.74 7.39 27.43
Wharton 16.57 11.19 22.50
Wheeler 11.41 6.58 17.46
Wichita 13.04 8.06 19.12
Wilbarger 14.38 9.13 20.51
Willacy 18.01 8.57 28.84
Williamson 9.59 5.83 14.53
Wilson 10.96 6.42 16.43
Winkler 14.59 8.97 21.16
Wise 11.81 6.78 18.19
Wood 13.02 7.16 20.28
Yoakum 12.61 7.27 18.88
Young 13.50 7.51 20.60
Zapata 14.68 6.34 24.50
Zavala 28.98 18.34 39.25

N/A, not applicable.

References

  1. Carle AC. Fitting multilevel models in complex survey data with design weights: Recommendations. BMC Medical Research Methodology. 2009;9:49. doi: 10.1186/1471-2288-9-49. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Chao C, Velicer C, Slezak JM, Jacobsen SJ. Correlates for completion of 3-dose regimen of HPV vaccine in female members of a managed care organization. Mayo Clinic Proceedings. 2009;84:864–870. doi: 10.4065/84.10.864. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chao C, Velicer C, Slezak JM, Jacobsen SJ. Correlates for human papillomavirus vaccination of adolescent girls and young women in a managed care organization. American Journal of Epidemiology. 2010;171:357–367. doi: 10.1093/aje/kwp365. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Congdon P. A multilevel model for cardiovascular disease prevalence in the US and its application to micro area prevalence estimates. International Journal of Health Geographics. 2009;8:6. doi: 10.1186/1476-072X-8-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Congdon P. A multilevel model for comorbid outcomes: Obesity and diabetes in the US. International Journal of Environmental Research and Public Health. 2010;7:333–352. doi: 10.3390/ijerph7020333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Conroy K, Rosenthal SL, Zimet GD, Yan J, Bernstein DI, Glynn S, et al. Human papillomavirus vaccine uptake, predictors of vaccination, and self-reported barriers to vaccination. Journal of Women’s Health. 2009;18:1679–1686. doi: 10.1089/jwh.2008.1329. [DOI] [PubMed] [Google Scholar]
  7. Dempsey A, Cohn L, Dalton V, Ruffin M. Patient and clinic factors associated with adolescent human papillomavirus vaccine utilization within a university-based health system. Vaccine. 2010;28:989–995. doi: 10.1016/j.vaccine.2009.10.133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Dorell C, Stokley S, Yankey D, Cohn A, Markowitz L. National, state, and local area vaccination coverage among adolescents aged 13-17 years: United States, 2009. Morbidity & Mortality Weekly Report. 2010;59:1018–1023. [PubMed] [Google Scholar]
  9. Dorell C, Stokley S, Yankey D, Liang JL, Markowitz L. National and state vaccination coverage among adolescents aged 13 through 17 years: United States, 2010. Morbidity and Mortality Weekly Report. 2011;60:1117–1123. [PubMed] [Google Scholar]
  10. Goldstein H. Multilevel statistical models. 4th ed John Wiley & Sons, Ltd; West Sussex, UK: 2010. [Google Scholar]
  11. Goodman MS. Comparison of small-area analysis techniques for estimating prevalence by race. Preventing Chronic Disease. 2010;7:A33. [PMC free article] [PubMed] [Google Scholar]
  12. Gottlieb SL, Brewer NT, Sternberg MR, Smith JS, Ziarnowski K, Liddon N, et al. Human papillomavirus vaccine initiation in an area with elevated rates of cervical cancer. Journal of Adolescent Health. 2009;45:430–437. doi: 10.1016/j.jadohealth.2009.03.029. [DOI] [PubMed] [Google Scholar]
  13. Hosmer DW, Lemeshow S. Applied logistic regression. 2nd ed John Wiley & Sons, Inc; Hoboken, NJ: 2000. [Google Scholar]
  14. Jain N, Stokley S, Yankey D. Vaccination coverage among adolescents aged 13-17 years: United States, 2007. Morbidity & Mortality Weekly Report. 2008;57:1100–1103. [PubMed] [Google Scholar]
  15. Jia H, Muennig P, Borawski E. Comparison of small-area analysis techniques for estimating county-level outcomes. American Journal of Preventive Medicine. 2004;26:453–460. doi: 10.1016/j.amepre.2004.02.004. [DOI] [PubMed] [Google Scholar]
  16. Kahn JA, Rosenthal SL, Jin Y, Huang B, Namakydoust A, Zimet GD. Rates of human papillomavirus vaccination, attitudes about vacci-nation, and human papillomavirus prevalence in young women. Obstetrics and Gynecology. 2008;111:1103–1110. doi: 10.1097/AOG.0b013e31817051fa. [DOI] [PubMed] [Google Scholar]
  17. Li W, Land T, Zi Z, Keithly L, Kelsey JL. Small-area estimation and prioritizing communities for tobacco control efforts in Massachusetts. American Journal of Public Health. 2009;99:470. doi: 10.2105/AJPH.2007.130112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Mendez-Luck CA, Yu H, Meng YY, Jhawar M, Wallace SP. Estimating health conditions for small areas: Asthma symptom prevalence for state legislative districts. Health Services Research. 2007;42:2389–2409. doi: 10.1111/j.1475-6773.2007.00793.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Neubrand TPL, Breitkopf CR, Rupp R, Breitkopf D, Rosenthal SL. Factors associated with completion of the human papillomavirus vaccine series. Clinical Pediatrics. 2009;48:966–969. doi: 10.1177/0009922809337534. [DOI] [PubMed] [Google Scholar]
  20. Pruitt SL, Schootman M. Geographic disparity, area poverty, and human papillomavirus vaccination. American Journal of Preventive Medicine. 2010;38:525–533. doi: 10.1016/j.amepre.2010.01.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Rabe-Hesketh S, Skrondal A. Multilevel modelling of complex survey data. Journal of the Royal Statistical Society: Series A (Statistics in Society) 2006;169:805–827. [Google Scholar]
  22. Rondy M, van Lier A, van de Kassteele J, Rust L, de Melker H. Determinants for HPV vaccine uptake in the Netherlands: A multilevel study. Vaccine. 2010;28:2070–2075. doi: 10.1016/j.vaccine.2009.12.042. [DOI] [PubMed] [Google Scholar]
  23. Rosenthal SL, Rupp R, Zimet GD, Meza HM, Loza ML, Short MB, et al. Uptake of HPV vaccine: Demographics, sexual history and values, parenting style, and vaccine attitudes. Journal of Adolescent Health. 2008;43:239–245. doi: 10.1016/j.jadohealth.2008.06.009. [DOI] [PubMed] [Google Scholar]
  24. Schneider KL, Lapane KL, Clark MA, Rakowski W. Using small-area estimation to describe county-level disparities in mammography. Preventing Chronic Disease. 2009;6:A125. [PMC free article] [PubMed] [Google Scholar]
  25. Siegel PZ, Frazier EL, Mariolis P, Brackbill RM, Smith C. Behavioral Risk Factor Surveillance, 1991: Monitoring progress toward the nation’s year 2000 health objectives. Morbidity and Mortality Weekly Report Surveillance Summaries. 1993;42(SS-4):1–21. [PubMed] [Google Scholar]
  26. U.S. Centers for Disease Control and Prevention [Retrieved September 2, 2011];Behavioral Risk Factor Surveillance System: 2008 summary data quality report. 2008a from ftp://ftp.cdc.gov/pub/Data/Brfss/2008_Summary_Data_Quality_Report.pdf.
  27. U. S. Centers for Disease Control and Prevention [Retrieved January 20, 2011];BRFSS Annual Survey Data: Survey data and documentation. 2008b from http://www.cdc.gov/brfss/technical_infodata/surveydata/2008.htm.
  28. U.S. Centers for Disease Control and Prevention [Retrieved January 20, 2011];U.S. Census populations with bridged race categories. 2009 from http://www.cdc.gov/nchs/nvss/bridged_race.htm.
  29. U.S. Food and Drug Administration [Retrieved January 20, 2011];FDA licenses new vaccine for prevention of cervical cancer and other diseases in females caused by human papillomavirus. 2006 from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108666.htm.
  30. Wong CA, Berkowitz Z, Dorell CG, Price RA, Lee J, Saraiya M. Human papillomavirus vaccine uptake among 9- to 17-year-old girls. Cancer. 2011;117:5612–5620. doi: 10.1002/cncr.26246. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Yu H, Meng YY, Mendez-Luck CA, Jhawar M, Wallace SP. Small-area estimation of health insurance coverage for California legislative districts. American Journal of Public Health. 2007;97:731–737. doi: 10.2105/AJPH.2005.077743. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Zimet GD, Liddon N, Rosenthal SL, Lazcano-Ponce E, Allen B. Chapter 24: Psychosocial aspects of vaccine acceptability. Vaccine. 2006;24(S3):201–209. doi: 10.1016/j.vaccine.2006.06.017. [DOI] [PubMed] [Google Scholar]

RESOURCES